Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07673016 · ClinicalTrials.gov registry record
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
A clinical trial, sponsored by Convergent Genomics.
- Recruiting
- Registry status
- 2,500
- Enrollment target
NCT07673016: Recruiting study, sponsored by Convergent Genomics.
NCT07673016 is a clinical trial that is actively recruiting participants, run by Convergent Genomics. The registered enrollment target is 2,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07673016 is actively recruiting participants, sponsored by Convergent Genomics.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
Primary Outcome
RFS is defined as the time from the urine specimen collection to the first histopathologically confirmed recurrence of urothelial carcinoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2034-12 |
What NCT07673016 shows while recruiting
NCT07673016 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07673016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07673016 about?
NCT07673016 is a clinical study titled "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer". This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
What is the current status of trial NCT07673016?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2019-10-15. Estimated completion is 2034-12.
Who is sponsoring clinical trial NCT07673016?
This trial is sponsored by Convergent Genomics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI